Fitzgerald Joseph Michael 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific EVP Joseph Fitzgerald Exercises Options, Receives Awards
What Happened
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), exercised/conversion of derivative awards and received new equity awards on Feb 12, 2026. He converted 3,462 derivative units into common stock and had 1,612 shares withheld to satisfy tax withholding (1,612 x $74.12 = $119,481). In addition, he was granted restricted stock units (RSUs) of 18,550 shares and 43,776 shares (total 62,326 RSUs) and received an option grant that vests over four years.
Key Details
- Transaction date: 2026-02-12; Form 4 filed 2026-02-17 (5 days after the transaction; typically Form 4 is due within two business days, so this appears late).
- Exercise/conversion: 3,462 derivative units converted to common stock (reported at $0 per share).
- Tax withholding: 1,612 shares were withheld/disposed to cover taxes at $74.12 per share, totaling $119,481 (transaction code F).
- Grants/awards: RSUs of 18,550 shares (F3) and 43,776 shares (F4) — total 62,326 RSUs; also an option grant that vests in four equal annual installments beginning Feb 12, 2027 (F5).
- Shares owned after the transaction: not specified in the provided filing data.
- Notable footnotes: F1 explains each RSU equals one share at settlement; F2 notes the reporting person disclaims beneficial ownership of shares held by his child; F3–F5 describe vesting schedules for the RSUs and option grant.
- Filing timeliness: filed Feb 17 for Feb 12 transactions — appears to be a late filing.
Context
- The exercise/conversion combined with share withholding for taxes is a routine post-exercise tax payment (share withholding), not an open-market sale for investment purposes.
- The awards (RSUs and option grant) are compensation grants that vest over future years and do not represent an immediate market purchase.
- For retail investors: grants and exercises by executives are common compensation events; purchases are generally more indicative of a direct bullish signal than routine exercises or tax withholdings.
Insider Transaction Report
Form 4
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-12+3,462→ 171,504 total - Tax Payment
Common Stock
2026-02-12$74.12/sh−1,612$119,481→ 169,892 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-12−3,462→ 6,924 totalExp: 2028-02-12→ Common Stock (3,462 underlying) - Award
Restricted Stock Units
[F1][F4]2026-02-12+18,550→ 18,550 totalExp: 2030-02-12→ Common Stock (18,550 underlying) - Award
Stock Option (Right to Buy)
[F5]2026-02-12+43,776→ 43,776 totalExercise: $74.12Exp: 2036-02-12→ Common Stock (43,776 underlying)
Holdings
- 5,234(indirect: By Children)
Common Stock
[F2]
Footnotes (5)
- [F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F2]The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
- [F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
- [F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
- [F5]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
Signature
/s/ Susan Thompson, Attorney-in-Fact|2026-02-17